NeuroSense Therapeutics is a clinical stage drug development company offering ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases.
The rationale behind the novel pathological targets of our drug, PrimeC, is supported by highly respected ALS experts and global Key Opinion Leaders, such as Professor Jeremy Shefner and Professor Vivian Drory.
In pre-clinical studies, PrimeC showed outstanding results, which were significantly better than any other outcome seen in this model before. Based on these results, NeuroSense filed a patent, and was granted an Orphan Drug Designation from the FDA, for the use of PrimeC in ALS patients.
NeuroSense Therapeutics is currently running two clinical trials in ALS patients, in Israel and the USA. Our dedicated team is working on a well-defined development plan to make an effective drug available within 4 years.